FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- BioRestorative Therapies, Inc. obtained approval from the FDA on August 6, 2025.Sub-event
FDA approved multiple Alnylam therapeutics for the company based in Cambridge.1 source
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
- FDA
Related events
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- Vitruvias Therapeutics, based in Auburn, Alabama, has received a recall notice from the FDA for its medication.
Coverage
Newest first; wire copies grouped- ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors